胎儿/新生儿同种免疫性血小板减少症免疫治疗方案的临床前评估
本研究以表达人HPA-1a表位的转基因小鼠血小板预免疫野生型雌鼠,建立模拟人胎儿/新生儿同种免疫性血小板减少症(FNAIT)的小鼠模型。该模型雌鼠与HPA-1a阳性雄鼠交配后产下严重血小板减少并伴出血表型的幼鼠。妊娠雌鼠给予多克隆静脉注射免疫球蛋白或针对HPA-1a表位的人单克隆阻断抗体后,新生鼠血小板计数显著升高、止血功能正常化并预防出血。
要点
- 建立同种抗原特异性小鼠模型,再现FNAIT关键临床特征。
- 妊娠雌鼠用多克隆IVIG或抗HPA-1a单克隆阻断抗体可提升新生鼠血小板并预防出血。
- 该模型可用于FNAIT新型治疗与预防方案的临床前开发与测试。
核心结论
- 表达人HPA-1a表位的转基因小鼠血小板预免疫雌鼠所产幼鼠再现FNAIT严重血小板减少与出血表型。
- 妊娠雌鼠给予多克隆静脉注射免疫球蛋白或抗HPA-1a人单克隆阻断抗体可显著升高新生鼠血小板计数、使止血正常化并预防出血。
- 该同种抗原特异性小鼠模型可用于FNAIT新型治疗与预防方案的临床前开发与测试。
研究设计与样本
- 野生型雌鼠以表达人HPA-1a表位(基于鼠GPIIIa骨架)的转基因小鼠血小板进行预免疫。
- 预免疫雌鼠与HPA-1a阳性雄鼠交配后评估新生鼠血小板减少与出血表型。
- 妊娠雌鼠分别给予多克隆静脉注射免疫球蛋白或针对HPA-1a表位的人单克隆阻断抗体。
主要发现
- 预免疫雌鼠产生针对HPA-1a的强同种免疫应答。
- 所产幼鼠出现严重血小板减少并伴出血表型。
- 妊娠雌鼠给予多克隆静脉注射免疫球蛋白或抗HPA-1a人单克隆阻断抗体后,新生鼠血小板计数显著升高、止血正常化并预防出血。
临床怎么用
- 该模型支持在临床前阶段评估抗HPA-1a单克隆阻断抗体与多克隆IVIG用于FNAIT治疗或预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a life-threatening bleeding disorder caused by maternal antibodies directed against paternally inherited antigens present on the surface of fetal platelets. The human platelet alloantigen HPA-1a (formerly known as the PlA1 alloantigen), is the most frequently implicated HPA for causing FNAIT in Whites. A single Leu33Pro amino acid polymorphism residing within the ∼50-amino-acid plexin-semaphorin-integrin domain near the N-terminus of the integrin β3 subunit (platelet membrane glycoprotein IIIa [GPIIIa]) is responsible for generating the HPA-1a and HPA-1b epitopes in human GPIIIa and serves as the central target for alloantibody-mediated platelet destruction. To simulate the etiology of human FNAIT, wild-type female mice were pre-immunized with platelets derived from transgenic mice engineered to express the human HPA-1a epitope on a murine GPIIIa backbone. These mice developed a strong alloimmune response specific for HPA-1a, and when bred with HPA-1a+ males, gave birth to severely thrombocytopenic pups that exhibited an accompanying bleeding phenotype. Administering either polyclonal intravenous immunoglobulin G or a human monoclonal blocking antibody specific for the HPA-1a epitope into pregnant female mice resulted in significant elevation of the neonatal platelet count, normalized hemostasis, and prevented bleeding. The establishment of an alloantigen-specific murine model that recapitulates many of the clinically important features of FNAIT should pave the way for the preclinical development and testing of novel therapeutic and prophylactic modalities to treat or prevent FNAIT in humans.
引用
- Zhi H, Ahlen MT, Skogen B, et al. Preclinical evaluation of immunotherapeutic regimens for fetal/neonatal alloimmune thrombocytopenia. Blood Adv. 2021. PMID: 34470046. doi:10.1182/bloodadvances.2021004371
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。